AngioDynamics, the Healthcare sector company, was revisited by a Wall Street analyst on December 12. Analyst John Young CFA from Canaccord Genuity maintained a Buy rating on the stock and has a $18.00 price target.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
John Young CFA has given his Buy rating due to a combination of factors including the recent developments in AngioDynamics’ product offerings. The company has initiated a new clinical trial for the AlphaReturn Blood Management System, which is designed to work alongside the already established AlphaVac F18 System. This trial aims to assess the safety and effectiveness of the combined systems in treating acute pulmonary embolism, with a primary completion date set for November 2026.
John Young CFA’s rating is based on the potential for the blood-return device to enhance the competitiveness of AngioDynamics in the pulmonary embolism market. The introduction of this system is expected to allow clinicians to perform more aggressive clot removal, aligning with similar successful mechanisms in the industry. This strategic move is anticipated to drive significant growth for the AlphaVac platform, with projected revenue growth of 41% year-over-year by fiscal year 2026.
According to TipRanks, Young CFA is a 3-star analyst with an average return of 4.8% and a 58.54% success rate. Young CFA covers the Healthcare sector, focusing on stocks such as AngioDynamics, Merit Medical Systems, and Staar Surgical.